US › Healthcare

Rallybio Corp (RLYB)

US · Healthcare · Biotechnology

$17.16+0.41%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$43.7M

EPS

$-1.09

EPS estimate

$-1.28

EPS came in at -1.09 against a street estimate of -1.28 — a beat of 14.8%.

Key statistics

Market cap

$89.6M

P/E

2.1

Forward P/E

0.0

P/B

0.95

Book value

$17.81

EPS (TTM)

$7.99

52-week high

$17.57

52-week low

$3.67

50-day MA

$16.44

200-day MA

$11.00

Beta

-0.85

Analyst view

Analysts rate Rallybio Corp a buy (1 buy, 3 hold, 0 sell out of 4) with an average price target of $8.00.

Shareholding

Insiders

24.20%

Institutions

86.13%

Largest institutional holders

Fund	Stake
FMR Inc	14.94%
Viking Global Investors LP	9.87%
Cormorant Asset Management, LLC	7.53%
TPG GP A, LLC	7.13%
Balyasny Asset Management LLC	7.09%
LAURION CAPITAL MANAGEMENT LP	5.70%
Nantahala Capital Management, LLC	5.66%
Pivotal bioVenture Partners Investment Advisor LLC	5.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rallybio Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.